← back to search

Lijie Tan

Shanghai Medical College of Fudan University · CN
Area of research
Surgery · Pulmonary and Respiratory Medicine
Research interest
Research interests include Esophageal Cancer Research and Treatment, Esophageal and GI Pathology, Gastric Cancer Management and Outcomes, and Lung Cancer Diagnosis and Treatment.
h-index
35
citations
3,916
works
173
NIH funding
primary concept
email

Recent publications

Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring
Molecular Cancer 2025cited by 9position: lastdoi
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial
Annals of Oncology 2025cited by 3position: middledoi
Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis.
Journal of Clinical Oncology 2025cited by 0position: middledoi
Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO/NCCES01 trial
Nature Medicine 2024cited by 182position: middledoi
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
The Lancet Respiratory Medicine 2024cited by 98position: middledoi
Perioperative outcomes and survival after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma
Journal of Thoracic and Cardiovascular Surgery 2024cited by 28position: lastdoi
Detection of the DNA methylation of seven genes contribute to the early diagnosis of lung cancer
Journal of Cancer Research and Clinical Oncology 2024cited by 19position: middledoi
Targeting p97–Npl4 interaction inhibits tumor Treg cell development to enhance tumor immunity
Nature Immunology 2024cited by 16position: middledoi
108O Surgical outcomes from RATIONALE-315: Randomized, double-blind, phase III study of perioperative tislelizumab with neoadjuvant chemotherapy in resectable NSCLC
ESMO Open 2024cited by 5position: middledoi
Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
Nature Medicine 2023cited by 86position: middledoi
Exosome-mediated metabolic reprogramming: Implications in esophageal carcinoma progression and tumor microenvironment remodeling
Cytokine & Growth Factor Reviews 2023cited by 25position: middledoi
Validity of Using Pathological Response as a Surrogate for Overall Survival in Neoadjuvant Studies for Esophageal Cancer: A Systematic Review and Meta-analysis
Annals of Surgical Oncology 2023cited by 25position: lastdoi
CACA guidelines for holistic integrative management of esophageal carcinoma
Holistic Integrative Oncology 2023cited by 12position: middledoi
Minimally invasive versus open esophagectomy for resectable thoracic esophageal cancer (NST 1502): a multicenter prospective cohort study
Journal of the National Cancer Center 2023cited by 10position: middledoi
miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways
Molecular Therapy — Nucleic Acids 2022cited by 112position: lastdoi
Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma: Early Results of a Multicenter Randomized Controlled Trial: the RAMIE Trial.
PubMed 2022cited by 89position: middledoi
Multiplexed nanomaterial-assisted laser desorption/ionization for pan-cancer diagnosis and classification
Nature Communications 2022cited by 61position: middledoi
Cisplatin resistance-related multi-omics differences and the establishment of machine learning models
Journal of Translational Medicine 2022cited by 49position: lastdoi
Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China
Diseases of the Esophagus 2022cited by 38position: middledoi
Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study)
BMC Cancer 2022cited by 34position: middledoi
The effect of enhanced recovery after minimally invasive esophagectomy: a randomized controlled trial
Surgical Endoscopy 2022cited by 30position: middledoi
Effects of pre-operative enteral immunonutrition for esophageal cancer patients treated with neoadjuvant chemoradiotherapy: protocol for a multicenter randomized controlled trial (point trial, pre-operative immunonutrition therapy)
BMC Cancer 2022cited by 16position: middledoi
Methionine oxidation of CLK4 promotes the metabolic switch and redox homeostasis in esophageal carcinoma via inhibiting MITF selective autophagy
Clinical and Translational Medicine 2022cited by 15position: middledoi
Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma
Annals of Surgery 2021cited by 187position: middledoi
Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
JAMA Surgery 2021cited by 183position: middledoi
LncRNA FAM83A-AS1 facilitates tumor proliferation and the migration via the HIF-1α/ glycolysis axis in lung adenocarcinoma
International Journal of Biological Sciences 2021cited by 126position: lastdoi
Landscape and dynamics of single tumor and immune cells in early and advanced‐stage lung adenocarcinoma
Clinical and Translational Medicine 2021cited by 110position: lastdoi
Dissecting the single-cell transcriptome network in patients with esophageal squamous cell carcinoma receiving operative paclitaxel plus platinum chemotherapy
Oncogenesis 2021cited by 60position: lastdoi
Exosomal O-GlcNAc transferase from esophageal carcinoma stem cell promotes cancer immunosuppression through up-regulation of PD-1 in CD8+ T cells
Cancer Letters 2020cited by 71position: middledoi
Lymph node dissection and recurrent laryngeal nerve protection in minimally invasive esophagectomy
Annals of the New York Academy of Sciences 2020cited by 35position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Yaxing Shen · Sun Yat-sen University11 papers (2012–2023)Qun Wang · Liaoning University11 papers (2012–2024)Hao Wang · Vrije Universiteit Amsterdam9 papers (2012–2022)Mingxiang Feng · Fudan University7 papers (2012–2017)Jun Yin · University of Electronic Science and Technology of China6 papers (2017–2024)Bentong Yu · Nanchang University5 papers (2021–2024)Zhencong Chen · Sun Yat-sen University5 papers (2021–2022)Zhigang Li · Huaihua University5 papers (2017–2022)Mengnan Zhao · Hebei Agricultural University5 papers (2021–2022)Chun Chen · Sun Yat-sen University5 papers (2017–2024)Cheng Zhan · Sun Yat-sen University5 papers (2021–2022)Yiwei Huang · Sun Yat-sen University5 papers (2021–2022)Hecheng Li · Shanghai Jiao Tong University5 papers (2017–2022)Hezhong Chen · Sun Yat-sen University Cancer Center4 papers (2019–2022)Guoshu Bi · Sun Yat-sen University4 papers (2021–2022)Zhengyang Hu · Shanghai Jiao Tong University4 papers (2021–2022)Jiaqi Liang · Chinese Academy of Medical Sciences & Peking Union Medical College4 papers (2021–2022)Yang Yang · Ningbo University4 papers (2019–2022) · 3 papers (2012–2013)Yingyong Hou · Shanghai Medical College of Fudan University3 papers (2015–2017)